We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

81 hedge funds and large institutions have $261M invested in UroGen Pharma in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1% more funds holding

Funds holding: 80 → 81 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 26

2.34% less ownership

Funds ownership: 68.21% → 65.87% (-2.3%)

9% less capital invested

Capital invested by funds: $287M → $261M (-$25.7M)

59% less call options, than puts

Call options by funds: $2.05M | Put options by funds: $4.97M

Holders
81
Holders Change
+1
Holders Change %
+1.25%
% of All Funds
1.43%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
25
Reduced
26
Closed
9
Calls
$2.05M
Puts
$4.97M
Net Calls
-$2.91M
Net Calls Change
-$1.67M

Top Buyers

Rank Fund Capital Flow
1
RHJA
Rice Hall James & Associates
California
+$2.14M
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$1.2M
3
BlackRock
BlackRock
New York
+$920K
4
AIM
ARK Investment Management
Florida
+$829K
5
Renaissance Technologies
Renaissance Technologies
New York
+$687K

Top Sellers

Rank Fund Capital Flow
1
Artisan Partners
Artisan Partners
Wisconsin
-$8.89M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.25M
3
PF
Phoenix Financial
Israel
-$1.72M
4
MIH
Meitav Investment House
Israel
-$934K
5
N
Nuveen
North Carolina
-$892K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$935K -$39.1K -1,867 -3%
California State Teachers Retirement System (CalSTRS)
27
California State Teachers Retirement System (CalSTRS)
California
$882K +$20.1K +958 +2%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$858K -$254K -12,100 -20%
Swiss National Bank
29
Swiss National Bank
Switzerland
$766K – – –
Charles Schwab
30
Charles Schwab
California
$740K +$22.3K +1,066 +3%
SAM
31
Shikiar Asset Management
New York
$720K -$96.4K -4,600 -10%
California Public Employees Retirement System
32
California Public Employees Retirement System
California
$710K -$16.8K -800 -2%
CBA
33
Coastal Bridge Advisors
Connecticut
$667K – – –
Citadel Advisors
34
Citadel Advisors
Florida
$655K +$238K +11,367 +46%
Bank of America
35
Bank of America
North Carolina
$616K +$445K +21,227 +164%
Wells Fargo
36
Wells Fargo
California
$613K +$118K +5,653 +20%
Renaissance Technologies
37
Renaissance Technologies
New York
$591K +$687K +32,800 New
EMG
38
ETF Managers Group
New Jersey
$590K +$82.1K +3,919 +14%
AG
39
Aperio Group
California
$566K +$184K +8,780 +39%
BHB
40
Bank Hapoalim BM
Israel
$541K +$629K +30,020 New
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$533K -$106K -5,075 -15%
PPA
42
Parametric Portfolio Associates
Washington
$519K +$8.3K +396 +1%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$516K +$65.6K +3,131 +12%
PAI
44
Palo Alto Investors
California
$441K – – –
AS
45
Altshuler Shaham
Israel
$423K – – –
UBS AM
46
UBS AM
Illinois
$404K – – –
AllianceBernstein
47
AllianceBernstein
Tennessee
$395K – – –
KHLMTHM
48
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet
Israel
$393K +$457K +21,823 New
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$359K – – –
Morgan Stanley
50
Morgan Stanley
New York
$310K +$283K +13,495 +366%
1
2
3 4

URGN Hedge Fund Activity: Q4 2020 in Review

81 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2020, worth a combined $261M — down 8.9% from $287M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new URGN positions and 9 closed out — a net gain of 1 holder — while 25 added to existing stakes and 26 trimmed.

The largest buyer was Rice Hall James & Associates, opening a new position worth an estimated $2.14M. The largest seller was Artisan Partners, exiting entirely with an estimated $8.89M sold.

  • 81 institutional investors held UroGen Pharma (URGN) as of Q4 2020, up from 80 in Q3 2020.
  • Funds reported $261M of UroGen Pharma stock for Q4 2020, down 8.9% quarter-over-quarter.
  • 10 funds opened new UroGen Pharma positions in Q4 2020 and 9 closed out, a net change of +1 holder.
  • The largest UroGen Pharma buyer in Q4 2020 was Rice Hall James & Associates, an estimated $2.14M added.
  • The largest UroGen Pharma seller in Q4 2020 was Artisan Partners, an estimated $8.89M sold.

Based on aggregated 13F filings for Q4 2020.